Latest Independent Expert Reports News

Little Green Pharma has issued a supplementary scheme booklet updating Cannatrek shareholders on the acquisition progress, including a revised timetable and the termination of a planned sale and leaseback of its WA production facility. Both companies’ boards continue to recommend the scheme, supported by an independent expert’s positive assessment.

Buxton Resources has agreed to sell its 49% stake in the Copper Wolf joint venture to IGO for approximately A$6.15 million, while retaining full ownership of surrounding tenements and regaining strategic freedom in Arizona.

Qoria Limited updates shareholders on its proposed merger with Aura Consolidated Group, highlighting Aura's robust financial performance and cost-saving initiatives. The merger remains unanimously recommended by Qoria's board, pending regulatory and shareholder approvals.

Insignia Financial has secured a crucial regulatory approval from APRA, advancing the proposed acquisition by Daintree BidCo. The deal now moves closer to a shareholder vote scheduled for mid-April.

The Supreme Court of New South Wales has approved the convening of meetings for National Storage REIT securityholders to vote on a $2.86 per security acquisition offer by a Brookfield-GIC consortium. The independent expert report supports the transaction as fair and reasonable, with the NSR Board unanimously recommending approval.

African Gold Ltd has proposed a scheme of arrangement for Montage Gold Corp to acquire 100% of its shares, with an independent expert endorsing the deal as fair and reasonable. The African Gold board unanimously recommends shareholder approval, setting the stage for a significant consolidation in Côte d'Ivoire’s gold sector.

Earth’s Energy has settled a dispute with minority shareholders over its South Australian geothermal joint venture, agreeing to payments and transferring its JV interest subject to shareholder approval.

Nova Minerals has signed a Scheme Implementation Deed to redomicile to the US, aiming for a primary NYSE listing while retaining a secondary ASX listing via CDIs. The move seeks to align corporate structure with its Alaskan operations and enhance access to US capital markets.

Apiam Animal Health shareholders convened on 3 February 2026 to vote on a scheme of arrangement proposing acquisition by Adamantem Capital Fund II, with the board unanimously recommending approval. The scheme offers $0.87 cash per share or scrip alternatives, pending final court approval.

ChemX Materials Limited remains suspended from ASX trading as it finalises overdue financial reports and secures informal funding, aiming for share reinstatement.

Cambium Bio has locked in a A$2.4 million strategic investment from Zheng Yang Biomedical Technology, reinforcing its push into pivotal Phase 3 trials for its dry eye disease treatment.

Elanor Investors Group has extended the deadline for dispatching its Notice of Meeting related to the Rockworth Capital Partners transaction, with the Extraordinary General Meeting now expected in early February 2026.